Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05981131 · ClinicalTrials.gov registry record

Follow up of Intravesical N-803 Plus BCG in BCG-Naive Non-Muscle Invasive Bladder Cancer (NMIBC)

A clinical trial of Non-muscle Invasive Bladder Cancer, sponsored by ImmunityBio.

Active
Registry status
6
Enrollment target
1
Study location

NCT05981131: Active study of Non-muscle Invasive Bladder Cancer, sponsored by ImmunityBio.

NCT05981131 is a study of Non-muscle Invasive Bladder Cancer that is active but no longer recruiting, run by ImmunityBio. The registered enrollment target is 6 participants, below the 227-participant average among 30 other Non-muscle Invasive Bladder Cancer trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05981131, a study of Non-muscle Invasive Bladder Cancer, is active but no longer recruiting, sponsored by ImmunityBio.

ACTIVE NOT RECRUITING
Registry status
6 participants
Enrollment target
1
Study location

Study Summary

The purpose of this clinical trial is to obtain long-term follow-up information and status of bladder cancer for patients who received study treatment in the QUILT-2.005 study.

Primary Outcome

Follow-up data on survival status, bladder cancer status (high-grade or low-grade), cystoscopy results (including number of cystoscopies done for each subject), biopsy results, upper tract evaluations, posttherapies and responses and outcomes of posttherapies, urine cytology results, and other medical history or treatments (if available) related to bladder cancer will be collected from subjects who were enrolled and treated in QUILT-2.005 phase 1b study with intravesical N-803 plus BCG. Study e

Conditions Studied

Non-muscle Invasive Bladder Cancer

Interventions

  • DRUG N803 plus Bacillus Calmette-Guerin (BCG)

Study Locations (1)

Hawaii

  • Island Urology - Honolulu

Trial Details

FieldValue
Enrollment Target 6 participants
Start Date 2023-08-17
Est. Completion 2033-08-30
ImmunityBio

46 total trials

What the registry record for NCT05981131 still lists

NCT05981131 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 6 participants, a relatively small participant target, below the 227-participant average among 30 other Non-muscle Invasive Bladder Cancer trials with a reported enrollment target (97% lower).

The record links to 1 condition, with Non-muscle Invasive Bladder Cancer appearing as the primary indexed condition, and to 1 intervention - of which N803 plus Bacillus Calmette-Guerin (BCG) is the first listed.

NCT05981131 reports a single indexed study location in Hawaii.

Frequently Asked Questions

What is clinical trial NCT05981131 about?

NCT05981131 is a clinical study titled "Follow up of Intravesical N-803 Plus BCG in BCG-Naive Non-Muscle Invasive Bladder Cancer (NMIBC)". The purpose of this clinical trial is to obtain long-term follow-up information and status of bladder cancer for patients who received study treatment in the QUILT-2.005 study.

What is the current status of trial NCT05981131?

This trial is currently active not recruiting. The enrollment target is 6 participants. The study started on 2023-08-17. Estimated completion is 2033-08-30.

What conditions does trial NCT05981131 study?

This clinical trial studies the following conditions: Non-muscle Invasive Bladder Cancer.

What interventions are being tested in trial NCT05981131?

The interventions under investigation include: N803 plus Bacillus Calmette-Guerin (BCG) (DRUG).

Who is sponsoring clinical trial NCT05981131?

This trial is sponsored by ImmunityBio, which has 46 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05981131 being conducted?

This trial has 1 study location across Hawaii. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Non-muscle Invasive Bladder Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05981131's enrollment target sits among peer trials

6 31st of 30 the lowest of 30 other Non-muscle Invasive Bladder Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Non-muscle Invasive Bladder Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT05981131, the US trial registry maintained by the National Library of Medicine. NCT05981131 (small enrollment · single site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.